TRAUMA
AAOS 2016: IV TXA reduced blood loss in hip arthroplasty for femoral neck fracture
138 patients undergoing hip arthroplasty for acute femoral neck fracture were randomized to receive either intravenous tranexamic acid (TXA) or placebo intraoperatively. The purpose of this study was to assess the efficacy of TXA for reducing blood loss and the incidence of blood transfusion, as well as to compare the complication rates between groups at 30- and 90-day follow-up. The results displayed a significantly lower calculated blood loss in the TXA group when compared to the placebo, and a non-significant difference between groups in transfusion requirement. Adverse events were not observed to significantly differ at 30- and 90-day follow-up.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
